Caroline Voltz joined the European Medicines Agency in 2007 in the regulatory affairs’ team where she was deeply involved in the implementation of the advanced therapies’ regulation. In 2009, she moved to the Biologicals’ office where she was involved in the flu pandemic and took over the scientific secretariat of the gene therapy working party. In 2103, she worked as a risk management specialist being involved in the revision of Risk Management Plan guidance. In 2016, she moved to the oncology, haematology and diagnostics office where she took over the scientific secretariat of the blood products working party (now haematology working party). She is scientific coordinator of the Cancer Medicine Forum dealing with treatment optimisation and is coordinating the European Specialised Expert Communities in Oncology and Haematology, communities of experts composed of around 180 experts from the European network of experts. Her main interests have been on regulatory aspects of advanced therapies, orphan medicines, international collaboration, and collaboration with stakeholders.
